Nasdaq

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

NEW HAVEN, Conn. and UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE: BHVN) and Merus N.V. (Nasdaq:MRUS), today announced a research collaboration ...

Chugai and Araris Biotech AG Enter License Agreement for Araris’ Linker-Payload ADC Technology AraLinQ®

[Reference] Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQᵀᴹ technology (Press ...

Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board

TAMPA, Fla. and LONDON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel ...
Morningstar

Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic

The program, licensed exclusively to BMS, represents the third ADC candidate using the company’s proprietary Tubutecan technology to reach the clinic. MUNICH, GERMANY, May 20, 2025 – Tubulis today ...
Nasdaq

Akari Advances Towards First-in-Human Trial With Novel ADC Payload

(RTTNews) - Akari Therapeutics, Plc (Nasdaq: AKTX) yesterday announced that it has initiated GMP manufacturing of its lead antibody-drug conjugate (ADC), AKTX-101, marking a pivotal step toward its ...
Rutland Herald

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement ...
Pharmabiz

Chugai Pharma and Araris Biotech ink license agreement for Araris' linker-payload ADC technology AraLinQ

Chugai Pharma and Araris Biotech ink license agreement for Araris' linker-payload ADC technology AraLinQ: Tokyo Wednesday, February 11, 2026, 11:00 Hrs [IST] Chugai Pharmaceutical ...
Mena FN

Chugai And Araris Biotech AG Enter License Agreement For Araris' Linker-Payload ADC Technology Aralinq®

(MENAFN- EIN Presswire) EINPresswire/ -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter "Chugai") and Araris Biotech AG (hereafter "Araris") today announced that Chugai has exercised its ...